HER3 expression, while common across other solid tumors, is especially relevant in lung cancer as it is expressed in 83% of NSCLC with the highest expression in EGFR-mutated NSCLC and is correlated with progression and poor relapse-free survival [64,65]. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.